{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T21:07:01Z","timestamp":1788815221042,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jaip.2025.11.024","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:58:53Z","timestamp":1764291533000},"page":"427-435.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparative Effectiveness of Tezepelumab and Dupilumab in Asthma: A Multinational Retrospective Cohort Study"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3485-9775","authenticated-orcid":false,"given":"Chun-Tse","family":"Hung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chien","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Yen","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Won","family":"Suk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2025.11.024_bib2","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.chest.2019.10.053","article-title":"Characterization of severe asthma worldwide: data from the International Severe Asthma Registry","volume":"157","author":"Wang","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2025.11.024_bib3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic therapies for severe asthma","volume":"386","author":"Brusselle","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.11.024_bib4","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/resp.14520","article-title":"Biologics for severe asthma\u2014which, when and why?","volume":"28","author":"Shah","year":"2023","journal-title":"Respirology"},{"key":"10.1016\/j.jaip.2025.11.024_bib5","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jaci.2023.01.020","article-title":"Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: a target trial emulation","volume":"151","author":"Akenroye","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.024_bib6","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/j.jaip.2025.04.015","article-title":"Comparative effectiveness of dupilumab versus mepolizumab and benralizumab in asthma: a multinational retrospective cohort study","volume":"13","author":"Hung","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.11.024_bib7","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1513\/AnnalsATS.202306-566OC","article-title":"Comparative effectiveness of mepolizumab, benralizumab, and dupilumab among patients with difficult-to-control asthma: a multicenter retrospective propensity-matched analysis","volume":"21","author":"Kearney","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jaip.2025.11.024_bib8","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s40265-022-01679-2","article-title":"Tezepelumab: first approval","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.jaip.2025.11.024_bib9","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1084\/jem.20062211","article-title":"Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells","volume":"204","author":"Allakhverdi","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaip.2025.11.024_bib10","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/14728222.2020.1783242","article-title":"Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma","volume":"24","author":"Gauvreau","year":"2020","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.jaip.2025.11.024_bib11","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1080\/13696998.2022.2074195","article-title":"Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison","volume":"25","author":"Menzies-Gow","year":"2022","journal-title":"J Med Econ"},{"key":"10.1016\/j.jaip.2025.11.024_bib12","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jaci.2022.11.021","article-title":"Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: a Bayesian network meta-analysis","volume":"151","author":"Nopsopon","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.024_bib13","doi-asserted-by":"crossref","first-page":"00248","DOI":"10.1183\/23120541.00248-2022","article-title":"Roles of real-world evidence in severe asthma treatment: challenges and opportunities","volume":"9","author":"Lee","year":"2023","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jaip.2025.11.024_bib14","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2500\/aap.2024.45.240018","article-title":"Real-world effectiveness of dupilumab versus benralizumab and mepolizumab","volume":"45","author":"Bleecker","year":"2024","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaip.2025.11.024_bib15","doi-asserted-by":"crossref","DOI":"10.4161\/tisb.24333","article-title":"Interleukin-4 and interleukin-13 cause barrier dysfunction in human airway epithelial cells","volume":"1","author":"Saatian","year":"2013","journal-title":"Tissue Barriers"},{"key":"10.1016\/j.jaip.2025.11.024_bib16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.71079\/ASIDE.IM.03222516","article-title":"TriNetX and real-world evidence: a critical review of its strengths, limitations, and bias considerations in clinical research","volume":"1","author":"Nassar","year":"2025","journal-title":"ASIDE Intern Med"},{"key":"10.1016\/j.jaip.2025.11.024_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1516126","article-title":"A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX","volume":"16","author":"Ludwig","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jaip.2025.11.024_bib18","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.jaip.2024.02.029","article-title":"Comparative impact of asthma biologics: a nationwide US claim-based analysis","volume":"12","author":"Al-Shaikhly","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.11.024_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2021-001003","article-title":"Characteristics of new adult users of mepolizumab with asthma in the USA","volume":"8","author":"Wu","year":"2021","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.jaip.2025.11.024_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/pds.70048","article-title":"Core concepts in pharmacoepidemiology: new-user designs","volume":"33","author":"Her","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jaip.2025.11.024_bib21","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","article-title":"Active-comparator design and new-user design in observational studies","volume":"11","author":"Yoshida","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jaip.2025.11.024_bib22","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.11.024_bib23","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.11.024_bib24","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1136\/thorax-2021-217032","article-title":"Asthma exacerbations are associated with a decline in lung function: a longitudinal population-based study","volume":"78","author":"Soremekun","year":"2023","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2025.11.024_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2024.111457","article-title":"Intention to treat and per protocol analyses: differences and similarities","volume":"173","author":"Molero-Calafell","year":"2024","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jaip.2025.11.024_bib26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41533-023-00350-x","article-title":"Chronic comorbid conditions and asthma exacerbation occurrence in a general population sample","volume":"33","author":"Baljet","year":"2023","journal-title":"NPJ Prim Care Respir Med"},{"key":"10.1016\/j.jaip.2025.11.024_bib27","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jaip.2021.11.016","article-title":"The role of comorbidities in difficult-to-control asthma in adults and children","volume":"10","author":"Gaffin","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.11.024_bib28","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1634\/theoncologist.2016-0198","article-title":"On the interpretation of the hazard ratio and communication of survival nenefit","volume":"22","author":"Sashegyi","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.jaip.2025.11.024_bib29","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/cea.13954","article-title":"Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases","volume":"51","author":"Hamilton","year":"2021","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2025.11.024_bib30","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41573-023-00750-1","article-title":"Type 2 chronic inflammatory diseases: targets, therapies and unmet needs","volume":"22","author":"Kolkhir","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaip.2025.11.024_bib32","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jaci.2015.05.052","article-title":"Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap syndromes","volume":"136","author":"Barnes","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.024_bib33","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.arbres.2024.10.006","article-title":"Asthma-COPD overlap\u2013a gateway to biological treatment","volume":"61","author":"Padilla-Galo","year":"2025","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.jaip.2025.11.024_bib34","article-title":"Tezepelumab in real-life practice: characteristics of patients commenced and efficacy in a nationwide, Danish cohort of patients with severe asthma","author":"Soendergaard","year":"2025","journal-title":"J Allergy Clin Immunol Pract."},{"key":"10.1016\/j.jaip.2025.11.024_bib35","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.jaip.2024.05.052","article-title":"Real-world data on tezepelumab in patients with severe asthma in Germany","volume":"12","author":"Biener","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.11.024_bib36","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1016\/j.jaip.2024.05.016","article-title":"Exploring definitions and predictors of response to biologics for severe asthma","volume":"12","author":"Scelo","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.11.024_bib37","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1016\/j.jaip.2022.07.016","article-title":"Assessment of real-world escalation to biologics in US patients with asthma","volume":"10","author":"Bender","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.11.024_bib38","doi-asserted-by":"crossref","DOI":"10.2196\/64354","article-title":"Imputation and missing indicators for handling missing longitudinal data: data simulation analysis based on electronic health record data","volume":"13","author":"Ehrig","year":"2025","journal-title":"JMIR Med Inform"},{"key":"10.1016\/j.jaip.2025.11.024_bib39","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.sapharm.2005.12.001","article-title":"Addressing the issue of channeling bias in observational studies with propensity scores analysis","volume":"2","author":"Lobo","year":"2006","journal-title":"Res Social Adm Pharm"},{"key":"10.1016\/j.jaip.2025.11.024_bib40","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1136\/thoraxjnl-2015-207530","article-title":"The natural history of severe asthma and influences of early risk factors: a population-based cohort study","volume":"71","author":"Chen","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2025.11.024_bib41","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/sim.7501","article-title":"Practical recommendations for reporting Fine-Gray model analyses for competing risk data","volume":"36","author":"Austin","year":"2017","journal-title":"Stat Med"},{"key":"10.1016\/j.jaip.2025.11.024_bib42","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","article-title":"Marginal structural models and causal inference in epidemiology","volume":"11","author":"Robins","year":"2000","journal-title":"Epidemiology"},{"key":"10.1016\/j.jaip.2025.11.024_bib43","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/sim.5984","article-title":"The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825011298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825011298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T07:37:38Z","timestamp":1780126658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219825011298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2213219825011298"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2025.11.024","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Effectiveness of Tezepelumab and Dupilumab in Asthma: A Multinational Retrospective Cohort Study","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2025.11.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}